BR0112365A - Combinações de estatinas, agentes estrogênicos e opcionalmente estrogênios - Google Patents
Combinações de estatinas, agentes estrogênicos e opcionalmente estrogêniosInfo
- Publication number
- BR0112365A BR0112365A BR0112365-3A BR0112365A BR0112365A BR 0112365 A BR0112365 A BR 0112365A BR 0112365 A BR0112365 A BR 0112365A BR 0112365 A BR0112365 A BR 0112365A
- Authority
- BR
- Brazil
- Prior art keywords
- esters
- estrogens
- alkyl
- optionally
- statins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMBINAçõES DE ESTATINAS, AGENTES ESTROGêNICOS E OPCIONALMENTE ESTROGêNIOS". A presente invenção refere-se a métodos de tratar distúrbios cardiovasculares e reduzir níveis de LDL no sangue que compreendem administrar uma estatina, um estrogênio e o composto das fórmulas (I ou II): em que Z é uma porção selecionada do grupo de: (III) em que R~ 1~ é selecionado entre H, OH ou os C~ 1~-C~ 4~ ésteres ou C~ 1~-C~ 12~ alquil éteres dos mesmos, benzilóxi ou halogênio; ou C~ 1~-C~ 4~ ésteres halogenados que incluem triflúormetil éter e triclorometil éter; R~ 2~, R~ 3~, R~ 5~ e R~ 6~ são H, OH ou C~ 1~-C~ 12~ ésteres ou C~ 1~-C~ 12~ alquil éteres dos mesmos, ou C~ 1~-C~ 4~ ésteres halogenados, ciano, C~ 1~C~ 6~ alquila ou triflúormetila, com a condição de que, quando R~ 1~ é H~ 1~, R~ 2~ não é OH: Y é a porção (IV) R~ 7~ e R~ 8~ são alquila ou concatenados para formar um anel contendo nitrogênio opcionalmente substituído ou um sal farmaceuticamente aceitável dos mesmos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21609600P | 2000-07-06 | 2000-07-06 | |
US21618400P | 2000-07-06 | 2000-07-06 | |
PCT/US2001/021085 WO2002003977A2 (en) | 2000-07-06 | 2001-06-29 | Combinations of statins, estrogenic agents and optionally estrogens |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0112365A true BR0112365A (pt) | 2003-05-13 |
Family
ID=26910656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0112365-3A BR0112365A (pt) | 2000-07-06 | 2001-06-29 | Combinações de estatinas, agentes estrogênicos e opcionalmente estrogênios |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1359940A2 (pt) |
JP (1) | JP2004502731A (pt) |
CN (1) | CN1468110A (pt) |
AU (1) | AU2001271785A1 (pt) |
BR (1) | BR0112365A (pt) |
CA (1) | CA2414060A1 (pt) |
MX (1) | MXPA02012896A (pt) |
WO (1) | WO2002003977A2 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8668914B2 (en) | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
CA2492754C (en) | 2002-07-24 | 2018-05-22 | Children's Hospital Medical Center | Compositions and products containing enantiomeric equol, and methods for their making |
CA2504682A1 (en) | 2002-10-29 | 2004-05-13 | Colorado State University Research Foundation | Use of equol for treating androgen mediated diseases |
US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
HUE055321T2 (hu) | 2015-10-01 | 2021-11-29 | Olema Pharmaceuticals Inc | Tetrahidro-1H-pirido[3,4-b]indol anti-ösztrogén hatóanyagok |
US10118910B2 (en) | 2015-12-09 | 2018-11-06 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective estrogen receptor downregulators |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
MX2019000200A (es) | 2016-07-01 | 2019-09-26 | G1 Therapeutics Inc | Agentes antiproliferativos basados en pirimidina. |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
BR112019013814A2 (pt) | 2017-01-06 | 2020-01-21 | G1 Therapeutics Inc | método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit. |
JP2020507566A (ja) | 2017-02-10 | 2020-03-12 | ジー1 セラピューティクス, インコーポレイテッド | ベンゾチオフェンエストロゲン受容体モジュレーター |
KR102659211B1 (ko) | 2017-06-29 | 2024-04-18 | 쥐원 쎄라퓨틱스, 인크. | G1t38의 형체 형태 및 그의 제조 방법 |
EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
WO2024097980A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein inhibitors |
WO2024097989A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2331318A1 (en) * | 1998-05-15 | 1999-11-25 | James Harrison Pickar | Compositions comprising 2-phenyl-indole compounds and estrogen formulations |
PT1076558E (pt) * | 1998-05-15 | 2003-11-28 | Wyeth Corp | 2-fenil-1-¬4-(2-aminoetoxi)-benzil|-indole em combinacao com estrogenios |
-
2001
- 2001-06-29 AU AU2001271785A patent/AU2001271785A1/en not_active Abandoned
- 2001-06-29 BR BR0112365-3A patent/BR0112365A/pt not_active IP Right Cessation
- 2001-06-29 MX MXPA02012896A patent/MXPA02012896A/es unknown
- 2001-06-29 CN CNA018150896A patent/CN1468110A/zh active Pending
- 2001-06-29 WO PCT/US2001/021085 patent/WO2002003977A2/en not_active Application Discontinuation
- 2001-06-29 CA CA002414060A patent/CA2414060A1/en not_active Abandoned
- 2001-06-29 JP JP2002508432A patent/JP2004502731A/ja active Pending
- 2001-06-29 EP EP01950826A patent/EP1359940A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CN1468110A (zh) | 2004-01-14 |
MXPA02012896A (es) | 2003-10-24 |
EP1359940A2 (en) | 2003-11-12 |
WO2002003977A2 (en) | 2002-01-17 |
JP2004502731A (ja) | 2004-01-29 |
AU2001271785A1 (en) | 2002-01-21 |
CA2414060A1 (en) | 2002-01-17 |
WO2002003977A3 (en) | 2003-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0112365A (pt) | Combinações de estatinas, agentes estrogênicos e opcionalmente estrogênios | |
BR0112364A (pt) | Combinações de bisfosfonatos, agentes estrogênicos e opcionalmente estrogênios | |
EA199700044A1 (ru) | Эстрогенные агенты | |
BR0112242A (pt) | Composições farmacêuticas de agentes estrogênicos | |
BR0206955A (pt) | Ligantes de receptores de canabinóides | |
CA2390295A1 (en) | A method for chemoprevention of prostate cancer | |
BE2015C026I2 (en) | 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens | |
BR0113776A (pt) | Composição de pirrolocarbazóis selecionados fundidos e método para tratar e prevenir várias doenças usando a citada composição | |
BR9815171A (pt) | Composto inibidor de pde iv aplicável no tratamento de doenças, particularmente de asma, em mamìferos e método para tratar um paciente sofrendo estados doentios. | |
AR005706A1 (es) | Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico | |
DE69831868D1 (en) | Antithrombosemittel | |
WO1993010741A3 (en) | Sex steroid activity inhibitors | |
BR0208678A (pt) | Composto, composição farmacêutica, uso de um composto | |
DE69830504D1 (de) | Antithrombotische mitteln | |
BR0112360A (pt) | Método para aumentar a atividade da sintase de óxido nìtrico | |
DK0900077T3 (da) | Anvendelse af en toremifene-metabolit til sænkning af serumcholesterolspejlet | |
DK1272481T3 (da) | 4-Flouralkyl-2H-benzopyraner med antiöstrogen virkning | |
JO2409B1 (en) | Second-phenyl carboxy amides are useful as lipid-lowering agents | |
BRPI0411285A (pt) | composto, processo para preparar um composto formulação farmacêutica, uso de um composto, e, método de prevenção ou tratamento de distúrbios | |
DE69917005D1 (de) | Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung | |
BR9812085A (pt) | "método para a sìntese de derivados de quinolina" | |
KR960037677A (ko) | 4-인돌릴피페라지닐 유도체 | |
BRPI0411772A (pt) | uso de derivados de biciclo[2.2.1]heptano para o preparo de composições farmacêuticas neuroprotetoras | |
MX9703232A (es) | Nuevos antagonistas del receptor muscarinico. | |
ATE535242T1 (de) | Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 7A E 8A ANUIDADES |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009. |